Drugs.com New Drug ApprovalsOriginal article
UCB Announces U.S. FDA Approval for Zilbrysq (zilucoplan) Autoinjector Self-administration for Adults Living with Generalized Myasthenia Gravis
RegulatoryapprovedZilbrysqPositive
AI Analysis
Summary
UCB announced on October 16, 2026 that the FDA approved a self-administered autoinjector for Zilbrysq (zilucoplan) for adults with generalized myasthenia gravis. The approval expands administration options for an already-marketed therapy.
Outcome Details
FDA approved the first self-administered autoinjector formulation of Zilbrysq (zilucoplan) for adults living with generalized myasthenia gravis.
Importance:6/10
Sentiment:
0.60
FDA approvalautoinjectorself-administrationgeneralized myasthenia graviscomplement inhibitorlabel expansion
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on October 16, 2026 9:10 PM